A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...
GlobalData on MSN
D3 Bio receives FDA clearance to advance KRAS inhibitor trials
The Phase II trial will assess the early efficacy, safety and pharmacokinetics of combining elisrasib with D3S 002.
Knowable Magazine reports on advancements in pancreatic cancer treatment, including new drugs, vaccines, and early diagnostic ...
The phase 3 KANDLELIT-007 trial (NCT07190248) evaluating the KRAS G12C inhibitor calderasib (MK-1084) plus subcutaneous pembrolizumab and berahyaluronidase alfa-pmph (Keytruda Qlex; SC pembrolizumab) ...
PAQ Therapeutics, a clinical-stage oncology company developing novel targeted protein degradation therapies for KRAS-driven cancers, today announced the closing of a Series B extension, bringing the ...
Oncogenic KRAS mutations are among the most prevalent driver events in solid tumors, with the KRAS G12D variant constituting the dominant allele in pancreatic ductal adenocarcinoma (PDAC) and a ...
KRAS G12D and G12V mutations in pancreatic ductal adenocarcinoma are associated with worse outcomes compared to KRAS wild-type. KRAS G12R mutation is linked to more favorable patient outcomes, with ...
Different Kirsten rat sarcoma virus (KRAS) mutations in pancreatic ductal adenocarcinoma show varying treatment responses, with G12D and G12V mutations linked to worse outcomes compared with wild type ...
Researchers at MUSC Hollings Cancer Center have discovered why a powerful cancer-causing gene mutation rarely appears in pancreatic tumors. The study, published in Cancer Research Communications, ...
Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results